Drug
Saracatinib clinical trials
Also written AZD0530.
- studies test it
- 33
- open now
- 0
- in phase 3
- 1
- first study started
- 2006
How studies write it
Studies that test it under each name
Name
Development codes
- AZD0530
- 26
Studies by the year they started
33 studies that test it; most in 2008 (10)
| Year | Studies |
|---|---|
| 2006 | 3 |
| 2007 | 5 |
| 2008 | 10 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 11
- Phase 2
- 23
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 26
National Cancer Institute (NCI) (12) · AstraZeneca (7) · Yale University (4) · Amsterdam UMC, location VUmc (1) · Joyce Marie Slingerland, MD (1) · NCIC Clinical Trials Group (1) · Stephen M. Strittmatter (1) · Sheffield Teaching Hospitals NHS Foundation Trust (1)
Often tested with
Tested in the same studies.
Gemcitabine (1) · Zoledronic Acid (1) · Carboplatin (1) · Paclitaxel (1)
Studies
Open first, then newest update. How each study uses saracatinib is read from its arms, and is right about nine times in ten.
Testing it · 33
- Saracatinib Trial TO Prevent FOPActive, not recruitingPhase 2Amsterdam UMC, location VUmcNCT04307953Written as AZD0530 Difumarate
- A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast CancerCompletedPhase 1/2Joyce Marie Slingerland, MDNCT01216176Written as AZD0530 (saracatinib)
- AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedPhase 1/2NCIC Clinical Trials GroupNCT00265876Written as AZD0530
- The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of AlcoholismCompletedPhase 1Yale UniversityNCT02262026Written as 125 mg AZD0530
- Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's DiseaseCompletedPhase 1Stephen M. StrittmatterNCT01864655Written as saracatinib
- Saracatinib and Alcohol DrinkingCompletedPhase 2Yale UniversityNCT02955186Written as Saracatinib
- Safety and Efficacy of Saracatinib In Subjects With LymphangioleiomyomatosisTerminatedPhase 2Baylor College of MedicineNCT02737202Written as saracatinib
- A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the LungTerminatedPhase 2Sarcoma Alliance for Research through CollaborationNCT00752206Written as Saracatinib
- Investigating the Interactions of AZD0530 With Alcohol in Social DrinkersCompletedPhase 1Yale UniversityNCT02732587Written as Saracatinib
- AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal CancerTerminatedPhase 2National Cancer Institute (NCI)NCT00397878Written as saracatinib
- A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's DiseaseCompletedPhase 2Yale UniversityNCT02167256Written as AZD0530 100mg daily
- SRC Inhibition as a Potential Target for Parkinson's Disease PsychosisStatus unknownEarly Phase 1King's College LondonNCT03661125Written as Saracatinib
- Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic CancerCompletedPhase 2National Cancer Institute (NCI)NCT00735917Written as saracatinib
- AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination ChemotherapyCompletedPhase 2National Cancer Institute (NCI)NCT00638937Written as saracatinib
- Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction CancerCompletedPhase 2National Cancer Institute (NCI)NCT00607594Written as saracatinib
- AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue SarcomaCompletedPhase 2National Cancer Institute (NCI)NCT00659360Written as saracatinib
- AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone TherapyCompletedPhase 2National Cancer Institute (NCI)NCT00513071Written as saracatinib
- SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone PainCompletedPhase 2Sheffield Teaching Hospitals NHS Foundation TrustNCT02085603Written as Saracatinib
- AZD0530 in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedPhase 2National Cancer Institute (NCI)NCT00528645Written as saracatinib
- The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)CompletedPhase 1Tony EissaNCT02116712Written as Saracatinib
See all 33 studies that test saracatinib →
Given in every arm · 1 — saracatinib is usual care beside what is tested
Codes
What other systems call saracatinib · ClinicalTrials.gg INT004999
- MeSH (NLM) C515233saracatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 9KD24QGH76SARACATINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q21098957saracatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C48378SaracatinibOne source FDA
- DrugBank DB11805One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C515233 | saracatinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 9KD24QGH76 | SARACATINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q21098957 | saracatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C48378 | Saracatinib | One source FDA |
| DrugBank | DB11805 | — | One source Wikidata |
Also registered as saracatinib difumarate (UNII 8R1DYT4EAW).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.